A carregar...
Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
PURPOSE: Ovarian cancer is the most lethal gynaecological malignancy. Despite the introduction of bevacizumab, standard chemotherapy has remained largely unchanged and the vast majority of patients will relapse within the first two years of diagnosis. However, results from recent clinical trials dem...
Na minha lista:
| Publicado no: | Arch Gynecol Obstet |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Berlin Heidelberg
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7524817/ https://ncbi.nlm.nih.gov/pubmed/32833070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00404-020-05677-1 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|